المؤلفون: Suset Dueñas-Disotuar, Ana Piñar-Gutiérrez, Irene de Lara-Rodríguez, Julia Sastre-Marcos, Emma Anda-Apiñániz, Amelia Oleaga-Alday, JC Galofré, Aida Orois, Victoria Alcázar-Lázaro, Laia Martínez-Guasch, Cecilia Sánchez-Ragnarsson, María Ángeles Gálvez-Moreno, Cristina Familiar-Casado, Tomás Martín-Hernández, Ana R. Romero-Lluch

المصدر: Frontiers in Endocrinology, Vol 15 (2025)

مصطلحات موضوعية: thyroid cancer, bone metastases, survival, skeletal-related events, radioiodine, multikinase inhibitors, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fendo.2024.1542771/full; https://doaj.org/toc/1664-2392

URL الوصول: https://doaj.org/article/e65e25aeee114ba8ab22c4eddde6e699

المؤلفون: Suset Dueñas-Disotuar, Ana Piñar-Gutiérrez, Irene de Lara-Rodríguez, Julia Sastre-Marcos, Emma Anda-Apiñániz, Amelia Oleaga-Alday, JC Galofré, Aida Orois, Victoria Alcázar-Lázaro, Laia Martínez-Guasch, Cecilia Sánchez-Ragnarsson, María Ángeles Gálvez-Moreno, Cristina Familiar-Casado, Tomás Martín-Hernández, Ana R. Romero-Lluch

المصدر: Frontiers in Endocrinology, Vol 15 (2024)

مصطلحات موضوعية: thyroid cancer, bone metastases, survival, skeletal-related events, radioiodine, multikinase inhibitors, antiresorptive agents, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fendo.2024.1466245/full; https://doaj.org/toc/1664-2392

URL الوصول: https://doaj.org/article/2e647576dfab4b04b1e56969f2f80754

المؤلفون: Alexander Burov, Ekaterina Grigorieva, Timofey Lebedev, Valeria Vedernikova, Vladimir Popenko, Tatiana Astakhova, Olga Leonova, Pavel Spirin, Vladimir Prassolov, Vadim Karpov, Alexey Morozov

المصدر: Frontiers in Molecular Biosciences, Vol 11 (2024)

مصطلحات موضوعية: ubiquitin-proteasome system, non-constitutive proteasomes, multikinase inhibitors, regorafenib, sorafenib, Biology (General), QH301-705.5

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fmolb.2024.1351641/full; https://doaj.org/toc/2296-889X

URL الوصول: https://doaj.org/article/4934c412afc54464983aec2d3baccb3d

المؤلفون: Alessandro Inno, Antonello Veccia, Giorgio Madonia, Alvise Berti, Roberto Bortolotti, Lorena Incorvaia, Antonio Russo, Orazio Caffo, Stefania Gori

المصدر: Frontiers in Cardiovascular Medicine, Vol 11 (2024)

مصطلحات موضوعية: immune checkpoint inhibitors, angiogenesis inhibitors, multikinase inhibitors, cardiovascular toxicity, hypertension, stroke, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fcvm.2024.1309100/full; https://doaj.org/toc/2297-055X

URL الوصول: https://doaj.org/article/e20c9a8a8b694069a5490bb7d83fd73d

المؤلفون: Yusra Zarlashat, Shakil Abbas, Abdul Ghaffar

المصدر: Cancers, Vol 16, Iss 11, p 2034 (2024)

مصطلحات موضوعية: hepatocellular carcinoma, hepatocytes, immune system, multikinase inhibitors, immune checkpoint inhibitors, immune microenvironment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.mdpi.com/2072-6694/16/11/2034; https://doaj.org/toc/2072-6694; https://doaj.org/article/a296c869f250406e88f599bb79deed99

الاتاحة: https://doi.org/10.3390/cancers16112034
https://doaj.org/article/a296c869f250406e88f599bb79deed99

المؤلفون: Martínez-Chantar, Maria L, Avila, Matias A, Lu, Shelly C

المصدر: Cancers. 12(10)

مصطلحات موضوعية: early diagnosis, hepatocellular carcinoma, immune checkpoint inhibitors, liquid biopsy, molecular mechanisms, multikinase inhibitors, risk factors, Oncology and Carcinogenesis

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/4kv8w7f7

المؤلفون: Daniela Dias, Inês Damásio, Pedro Marques, Helder Simões, Ricardo Rodrigues, Branca Maria Cavaco, Valeriano Leite

المصدر: European Thyroid Journal, Vol 12, Iss 3, Pp 1-6 (2023)

مصطلحات موضوعية: advanced follicular thyroid carcinoma, gemox (gemcitabine plus oxaliplatin), multikinase inhibitors, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

Relation: https://etj.bioscientifica.com/view/journals/etj/12/3/ETJ-22-0227.xml; https://doaj.org/toc/2235-0802

URL الوصول: https://doaj.org/article/64bd2f9e0d8c41a89065d357fab83384

المؤلفون: Songporn Oranratnachai, Sasivimol Rattanasiri, Ekaphop Sirachainan, Amarit Tansawet, Nilubol Raunroadroong, Gareth J. McKay, John Attia, Ammarin Thakkinstian

المصدر: Cancer Medicine, Vol 12, Iss 3, Pp 3046-3053 (2023)

مصطلحات موضوعية: FOLFOX, hepatocellular carcinoma, multikinase inhibitors, real‐world data, Sorafenib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2045-7634

URL الوصول: https://doaj.org/article/8d6555e6533343609bcc614e15de136d

المؤلفون: Neus Basté Rotllan

المصدر: Cancer Medicine, Vol 11, Iss S1, Pp 10-16 (2022)

مصطلحات موضوعية: immunosuppressed patients, multikinase inhibitors, systemic treatment, thyroid carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2045-7634

URL الوصول: https://doaj.org/article/0ff17f65ebda41939668d84e6faf1ec0

المؤلفون: Elena Navarro‐Gonzalez

المصدر: Cancer Medicine, Vol 11, Iss S1, Pp 54-58 (2022)

مصطلحات موضوعية: bisphosphonates, bone metastases, denosumab, lenvatinib, multikinase inhibitors, radioiodine‐refractory thyroid cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2045-7634

URL الوصول: https://doaj.org/article/3a7c94ecc46a45a880ecbffbae183ad9

المؤلفون: Marcel Sambo

المصدر: Cancer Medicine, Vol 11, Iss S1, Pp 26-32 (2022)

مصطلحات موضوعية: differentiated thyroid carcinoma, multikinase inhibitors, multiple primary malignant neoplasms, synchronous/metachronous cancers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2045-7634

URL الوصول: https://doaj.org/article/5a6971fcb12b41f6a3f63836fbc09bb5

المؤلفون: Paula Jimenez‐Fonseca

المصدر: Cancer Medicine, Vol 11, Iss S1, Pp 17-25 (2022)

مصطلحات موضوعية: cardiovascular disease, hypertension, lenvatinib, multikinase inhibitors, sorafenib, thyroid carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2045-7634

URL الوصول: https://doaj.org/article/e4bebb6f7dd94b7c940cbfa5728e4582

المؤلفون: Urbano Anido Herranz

المصدر: Cancer Medicine, Vol 11, Iss S1, Pp 47-53 (2022)

مصطلحات موضوعية: lenvatinib, multikinase inhibitors, radioiodine‐refractory thyroid cancer, sorafenib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2045-7634

URL الوصول: https://doaj.org/article/ea4da9504a3b4c5a801b708b725ab9ff

المؤلفون: Maple Ye Feng, Landon L. Chan, Stephen Lam Chan

المصدر: Current Oncology, Vol 29, Iss 8, Pp 5489-5507 (2022)

مصطلحات موضوعية: advanced hepatocellular carcinoma, systemic therapies, multikinase inhibitors, immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.mdpi.com/1718-7729/29/8/434; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

URL الوصول: https://doaj.org/article/9b6f1eb5348344eaad2d936072fea0d6

المؤلفون: You-Liang Lai, Kai-Hung Wang, Hsing-Pang Hsieh, Wan-Ching Yen

المصدر: Journal of Biomedical Science, Vol 29, Iss 1, Pp 1-19 (2022)

مصطلحات موضوعية: Hepatocellular carcinoma, Multikinase inhibitors, Aurora kinases, Sorafenib resistance, Medicine

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1423-0127

URL الوصول: https://doaj.org/article/da5b6894f2c24f4c97694cf8c4404855

المؤلفون: Vaganova, I. Y., Petkau, V. V., Ваганова, И. Ю., Петкау, В. В.

المصدر: Сборник статей

مصطلحات موضوعية: HEPATOCELLULAR CANCER, FUNCTIONAL STATUS, MULTIKINASE INHIBITORS, ГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК, ФУНКЦИОНАЛЬНЫЙ СТАТУС, МУЛЬТИКИНАЗНЫЕ ИНГИБИТОРЫ

وصف الملف: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; Ваганова, И. Ю. Опыт терапии распространенного гепатоцеллюлярного рака мультикиназными ингибиторами у пациентов со сниженным функциональным статусом (ECOG 2) / И. Ю. Ваганова, В. В. Петкау. - Текст электронный. // Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г. – Екатеринбург : УГМУ, 2023. – C. 2133-2136.; http://elib.usma.ru/handle/usma/14336

الاتاحة: http://elib.usma.ru/handle/usma/14336

المؤلفون: Belli, Valentina, Napolitano, Stefania, De Falco, Vincenzo, Suarato, Gabriella, Perrone, Alessandra, Guerrera, Luigi Pio, Martini, Giulia, Della Corte, Carminia Maria, Martinelli, Erika, Morgillo, Floriana, Turano, Mimmo, Furia, Maria, Argenziano, Giuseppe, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa

المساهمون: Belli, Valentina, Napolitano, Stefania, De Falco, Vincenzo, Suarato, Gabriella, Perrone, Alessandra, Guerrera, Luigi Pio, Martini, Giulia, Della Corte, Carminia Maria, Martinelli, Erika, Morgillo, Floriana, Turano, Mimmo, Furia, Maria, Argenziano, Giuseppe, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa

مصطلحات موضوعية: Metastatic melanoma, Drug resistance, BRAF and MEK inhibitors, EMT transition, EPH signaling, DDR signaling, multikinase inhibitors, ALW‐II‐41‐27 inhibitor

Relation: volume:8; issue:1; firstpage:1; lastpage:11; numberofpages:11; journal:TRANSLATIONAL MEDICINE COMMUNICATIONS; https://hdl.handle.net/11588/949128; https://transmedcomms.biomedcentral.com/articles/10.1186/s41231-022-00133-5#citeas

الاتاحة: https://hdl.handle.net/11588/949128
https://doi.org/10.1186/s41231-022-00133-5
https://transmedcomms.biomedcentral.com/articles/10.1186/s41231-022-00133-5#citeas

المؤلفون: Rui Sousa Martins, Tito Teles Jesus, Luís Cardoso, Paula Soares, João Vinagre

المصدر: Journal of Personalized Medicine; Volume 13; Issue 7; Pages: 1132

مصطلحات موضوعية: MTC, RET, signaling pathways, TKIs, multikinase inhibitors, RET -specific inhibitors

وصف الملف: application/pdf

Relation: https://dx.doi.org/10.3390/jpm13071132

الاتاحة: https://doi.org/10.3390/jpm13071132

المؤلفون: I. A. Dzhanyan, M. N. Khagazheeva, V. V. Breder, D. I. Yudin, I. V. Pogrebnyakov, A. E. Kuzminov, E. Yu. Antonova, N. M. Starostin, И. А. Джанян, М. Н. Хагажеева, В. В. Бредер, Д. И. Юдин, И. В. Погребняков, А. Е. Кузьминов, Е. Ю. Антонова, Н. М. Старостин

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2023); 10-17 ; Медицинский Совет; № 11 (2023); 10-17 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: симптоматическая терапия, hepatic portal vein thrombosis, multikinase inhibitors, sorafenib, cirrhosis decompensation, first-line therapy, symptomatic therapy, тромбоз воротной вены, мультикиназные ингибиторы, сорафениб, декомпенсация цирроза, первая линия терапии

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7663/6797; Бредер В.В., Базин И.С., Балахнин П.В., Виршке Э.Р., Косырев В.Ю., Ледин Е.В. и др. Практические рекомендации по лекарственному лечению больных злокачественными опухолями печени и желчевыводящей системы. Злокачественные опухоли. 2022;12(3s2-1):467–529. https://doi.org/10.18027/2224-5057-2022-12-3s2-467-529.; Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ; 2018. 250 с. Режим доступа: https://glavonco.ru/upload/pages/cancer-register/statistika_zabol_2017.pdf.; Cheng A.L., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.Y. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. https://doi.org/10.1016/j.jhep.2021.11.030.; Morse M.A., Sun W., Kim R., He A.R., Abada P.B., Mynderse M., Finn R.S. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2019;25(3):912–920. https://doi.org/10.1158/1078-0432.CCR-18-1254.; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.; Hegde P.S., Wallin J.J., Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt 2):117–124. https://doi.org/10.1016/j.semcancer.2017.12.002.; Lu L.C., Hsu C., Shao Y.Y., Chao Y., Yen C.J., Shih I.L. et al. Differential OrganSpecific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer. 2019;8(6):480–490. https://doi.org/10.1159/000501275.; Kim H.S., Hong J.Y., Cheon J., Kim I., Kim C.G., Kang B. et al. Different organspecific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC). J Clin Oncol. 2020;38(Suppl. 15):4584–4584. https://doi.org/10.1200/JCO.2020.38.15_suppl.4584.; Yoong K.F., McNab G., Hübscher S.G., Adams D.H. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol. 1998;160(8):3978–3988. https://doi.org/10.4049/jimmunol.160.8.3978.; Lee M.S., Ryoo B.Y., Hsu C.H., Numata K., Stein S., Verret W. et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. https://doi.org/10.1016/S1470-2045(20)30156-X.; Fulgenzi C.A.M., Cheon J., D’Alessio A., Nishida N., Ang C., Marron T.U. et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022;175:204–213. https://doi.org/10.1016/j.ejca.2022.08.024.; Zhu A.X., Duda D.G., Sahani D.V., Jain R.K. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292–301. https://doi.org/10.1038/nrclinonc.2011.30.; Motz G.T., Santoro S.P., Wang L.P., Garrabrant T., Lastra R.R., Hagemann I.S., et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–615. https://doi.org/10.1038/nm.3541.; Wallin J.J., Bendell J.C., Funke R., Sznol M., Korski K., Jones S. et al. Atezolizumab in combination with bevacizumab enhances antigenspecific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. https://doi.org/10.1038/ncomms12624.; Chen D.S., Hurwitz H. Combinations of Bevacizumab With Cancer Immunotherapy. Cancer J. 2018;24(4):193–204. https://doi.org/10.1097/PPO.0000000000000327.; Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. https://doi.org/10.1038/nature14011.; Finn R.S., Bentley G., Britten C.D., Amado R., Busuttil R.W. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int. 2009;29(2):284–290. https://doi.org/10.1111/j.1478-3231.2008.01762.x.; Boige V., Malka D., Bourredjem A., Dromain C., Baey C., Jacques N. et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17(8):1063–1072. https://doi.org/10.1634/theoncologist.2011-0465.; Siegel A.B., Cohen E.I., Ocean A., Lehrer D., Goldenberg A., Knox J.J. et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992–2928. https://doi.org/10.1200/JCO.2007.15.9947.; Thomas M.B., Garrett-Mayer E., Anis M., Anderton K., Bentz T., Edwards A. et al. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology. 2018;94(6):329–339. https://doi.org/10.1159/000485384.; Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.Y. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745.; Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.Y. et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(Suppl. 3):267–267. https://doi.org/10.1200/JCO.2021.39.3_suppl.267.; De Franchis R., Bosch J., Garcia-Tsao G., Reiberger T., Ripoll C. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. https://doi.org/10.1016/j.jhep.2021.12.022.; https://www.med-sovet.pro/jour/article/view/7663

الاتاحة: https://www.med-sovet.pro/jour/article/view/7663
https://doi.org/10.21518/ms2023-177

المؤلفون: You-Liang Lai (11520730), Kai-Hung Wang (11987977), Hsing-Pang Hsieh (139595), Wan-Ching Yen (11987980)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Genetics, Molecular Biology, Pharmacology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Hepatocellular carcinoma, Multikinase inhibitors, Aurora kinases, Sorafenib resistance

Relation: https://figshare.com/articles/presentation/Additional_file_1_of_Novel_FLT3_AURK_multikinase_inhibitor_is_efficacious_against_sorafenib-refractory_and_sorafenib-resistant_hepatocellular_carcinoma/18865012

الاتاحة: https://doi.org/10.6084/m9.figshare.18865012.v1